Company Filing History:
Years Active: 2021-2023
Title: Innovations of Matthew Alexander Perry
Introduction
Matthew Alexander Perry is an accomplished inventor based in Uncasville, CT (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit phosphodiesterase 4 (PDE4). With a total of two patents to his name, Perry's work is recognized for its potential impact on treating various diseases.
Latest Patents
Perry's latest patents include "Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors." This invention relates to boron-containing compounds that inhibit PDE4, along with pharmaceutical compositions that utilize these compounds for treating diseases, conditions, or disorders that can be ameliorated by PDE4 inhibition. Another notable patent is for the PDE4 inhibitor "(R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol," which includes the crystalline monohydrate form of the compound.
Career Highlights
Matthew Perry is currently employed at Pfizer Corporation, a leading global pharmaceutical company. His work at Pfizer has allowed him to focus on innovative research and development in the pharmaceutical sector.
Collaborations
Perry has collaborated with notable colleagues such as Joseph Walter Strohbach and David Clive Blakemore. Their combined expertise has contributed to the advancement of their projects and innovations.
Conclusion
Matthew Alexander Perry's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a significant inventor. His work continues to pave the way for advancements in medical treatments.